2022 AACR Annual Meeting Update
The 2022 AACR meeting featured pancreatic cancer research in artificial intelligence, screening and earlier detection, and vaccines.
The 2022 AACR meeting featured pancreatic cancer research in artificial intelligence, screening and earlier detection, and vaccines.
Elizabeth O’Connor has a PALB2 genetic mutation so her stage IV pancreatic cancer has responded to immunotherapy.
Dr. Neeha Zaidi is the lead investigator of an immunotherapy trial using a vaccine for people at high risk for pancreatic cancer.
Clinical trials were reported on at ASCO GI 2022, as well as reports on COVID, virtual tumor boards, and racial disparities in treatment.
As the year winds down Let’s Win provides an overall look at the highlights of 2021 in pancreatic cancer science.
A platform clinical trial evaluates immunotherapy combinations with standard of care treatment for advanced pancreatic cancer.
While immunotherapy and other targeted treatments involving monoclonal antibodies have been successful in other cancers, pancreatic cancer has been notoriously tough to target because of a lack of suitable cell surface targets to which the antibodies can bind. But a new target has been identified, and researchers are hopeful that an investigational drug that homes…
Two clinical trials in the Lustgarten Foundation’s Clinical Accelerator are testing different combinations of immunotherapy.
Researchers are testing whether a vaccine can heighten the body’s immune response to pancreatic cancer after surgical removal of the tumor.
Dr. William Freed-Pastor is testing a combination of three types of immunotherapy to attack pancreatic tumors.